Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Targeting CD19 and CD22, in Pediatric Patients with Rel Lymphoblastic Leukemia (r/r B-ALL): Amelia Study

Blood

134, 2620-2620

DOI: 10.1182/blood-2019-123424

Citation Report

#	Article	IF	Citations
1	Chimeric Antigen Receptor T-Cells in B-Acute Lymphoblastic Leukemia: State of the Art and Future Directions. Frontiers in Oncology, 2020, 10, 1594.	1.3	46
2	Gene Modified CAR-T Cellular Therapy for Hematologic Malignancies. International Journal of Molecular Sciences, 2020, 21, 8655.	1.8	13
3	Bispecific Chimeric Antigen Receptor T Cell Therapy for B Cell Malignancies and Multiple Myeloma. Cancers, 2020, 12, 2523.	1.7	27
4	Updates in Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Lymphoma and Leukemia from the Annual Meeting of American Society of Hematology 2019. Critical Reviews in Oncology/Hematology, 2020, 152, 103007.	2.0	0
5	Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. Journal of Hematology and Oncology, 2020, 13, 70.	6.9	100
6	Recent advances in CAR-T cell engineering. Journal of Hematology and Oncology, 2020, 13, 86.	6.9	192
7	Anti-CD19 CAR-T cells: Digging in the dark side of the golden therapy. Critical Reviews in Oncology/Hematology, 2021, 157, 103096.	2.0	10
8	Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cellâ€“Redirected Bispecific Antibodies. Journal of Clinical Oncology, 2021, 39, 444-455.	0.8	18
9	Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments. Frontiers in Immunology, 2020, 11, 569117.	2.2	26
10	Preclinical and clinical advances in dualâ€target chimeric antigen receptor therapy for hematological malignancies. Cancer Science, 2021, 112, 1357-1368.	1.7	19
11	CAR-T cells and BiTEs in solid tumors: challenges and perspectives. Journal of Hematology and Oncology, 2021, 14, 65.	6.9	50
12	The antigenâ€binding moiety in the driver's seat of CARs. Medicinal Research Reviews, 2022, 42, 306-342.	5.0	21
13	Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms. Leukemia, 2021, 35, 3044-3058.	3.3	29
14	CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities. Frontiers in Immunology, 2021, 12, 693016.	2.2	45
15	Investigational immunotherapy targeting CD19 for the treatment of acute lymphoblastic leukemia. Expert Opinion on Investigational Drugs, 2021, 30, 773-784.	1.9	8
16	CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nature Medicine, 2021, 27, 1419-1431.	15.2	273
19	Emerging Monoclonal Antibody Therapy for the Treatment of Acute Lymphoblastic Leukemia. Biologics: Targets and Therapy, 2021, Volume 15, 419-431.	3.0	1
20	Born to survive: how cancer cells resist CAR T cell therapy. Journal of Hematology and Oncology, 2021, 14, 199.	6.9	59

#	Article	IF	Citations
22	CAR T-cells in acute lymphoblastic leukemia: Current results. Bulletin Du Cancer, 2021, 108, S40-S54.	0.6	3
23	The Past, Present, and Future of Clinically Applied Chimeric Antigen Receptor-T-Cell Therapy. Pharmaceuticals, 2022, 15, 207.	1.7	5
24	Engineering T-cells with chimeric antigen receptors to combat hematological cancers: an update on clinical trials. Cancer Immunology, Immunotherapy, 2022, , 1.	2.0	5
25	Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Adults. Cancers, 2022, 14, 1805.	1.7	10
26	CARâ€T cell therapy in paediatric acute lymphoblastic leukaemia â€“ past, present and future. British Journal of Haematology, 2020, 191, 617-626.	1.2	5
27	Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting. Experimental Hematology and Oncology, 2022, 11, .	2.0	8
28	Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function. Blood Advances, 0, , .	2.5	2
29	Optimal Use of Novel Immunotherapeutics in B-Cell Precursor ALL. Cancers, 2023, 15, 1349.	1.7	0
31	Chimeric Antigen Receptor T-Cell Therapy in Acute Lymphoblastic Leukemia. , 2024, , 233-245.		0